Text Among the spectrum of idiopathic inflammatory myopathies (IIM), two distinct subtypes—anti-synthetase syndrome (ASyS) and anti-MDA5-positive ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and ...

The fifth ILD Summit, hosted by Boehringer Ingelheim, took place in the UAE, a gathering where the world’s leading ...

Examining the impact of geographic distance and social vulnerability on interstitial lung disease care and outcomes is essential, as access barriers disproportionately affect h ...

Genetic predisposition to rheumatoid arthritis increases the risk of interstitial lung disease by 15.5%, as shown by Mendelian randomization analysis. The study used 52 single nucleotide polymorphisms ...

At first, it just seemed like a post-pandemic hangover: scattered patients drifting into Yorkshire clinics with damaged lungs ...

The most common chronic progressive fibrosing ILD is IPF.1,2 PPF is another form of progressive fibrotic lung disease that ...

United Therapeutics' stock surged after IPF trial results and what future pivotal trials could mean for investors. See here ...

The accelerated FDA approval of Bayer's Hyrnuo covers treatment of advanced cases of non-small cell lung cancer with HER2 ...

U.S. FDA Approves HYRNUO® (sevabertinib) for Previously Treated Patients with HER2-Mutated Locally Advanced or Metastatic Non-Squamous NSCLC ...

The FDA has granted an accelerated approval to sevabertinib (Hyrnuo) for the treatment of adult patients with previously ...

Select your location to view local American Lung Association events and news near you.